These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 35449580)

  • 61. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
    Jensen TI; Axelgaard E; Bak RO
    Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Production of Human CRISPR-Engineered CAR-T Cells.
    Agarwal S; Wellhausen N; Levine BL; June CH
    J Vis Exp; 2021 Mar; (169):. PubMed ID: 33779622
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
    Xu Y; Chen C; Guo Y; Hu S; Sun Z
    Front Immunol; 2022; 13():848327. PubMed ID: 35300341
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The applications of CRISPR screen in functional genomics.
    Qi X; Zhang J; Zhao Y; Chen T; Xiang Y; Hui J; Cai D; Liu Y; Xia L; Yu T; Li G
    Brief Funct Genomics; 2017 Jan; 16(1):34-37. PubMed ID: 27329784
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A New Era of Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated Protein 9 Gene Editing Technology in Cardiovascular Diseases: Opportunities, Challenges, and Perspectives.
    Rahul K; Singh SK; Kumar S; Tewarson V; Hakim MZ; Kaushik K; Kumar S; Kumar B
    Heart Views; 2023; 24(4):201-207. PubMed ID: 38188709
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy.
    Chen C; Wang Z; Qin Y
    Exp Hematol Oncol; 2023 Nov; 12(1):95. PubMed ID: 37964355
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Using CRISPR to enhance T cell effector function for therapeutic applications.
    Freen-van Heeren JJ
    Cytokine X; 2021 Mar; 3(1):100049. PubMed ID: 33604565
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
    Li Y; Glass Z; Huang M; Chen ZY; Xu Q
    Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Strategies for the CRISPR-Based Therapeutics.
    Li B; Niu Y; Ji W; Dong Y
    Trends Pharmacol Sci; 2020 Jan; 41(1):55-65. PubMed ID: 31862124
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.
    Yang Z; Pietrobon V; Bobbin M; Stefanson O; Yang J; Goswami A; Alphson B; Choi H; Magallanes K; Cai Q; Barrett D; Wang B; Qi LS; Marincola FM
    J Transl Med; 2023 Feb; 21(1):158. PubMed ID: 36855120
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genome modification by CRISPR/Cas9.
    Ma Y; Zhang L; Huang X
    FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine.
    Khoshandam M; Soltaninejad H; Mousazadeh M; Hamidieh AA; Hosseinkhani S
    Genes Dis; 2024 Jan; 11(1):268-282. PubMed ID: 37588217
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.
    Banda A; Impomeni O; Singh A; Baloch AR; Hu W; Jaijyan DK
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932365
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chemical Modification and Transformation Strategies of Guide RNAs in CRISPR-Cas9 Gene Editing Systems.
    Zhang Y; Wang Q; Wang J; Tang X
    Chempluschem; 2021 Mar; 86(4):587-600. PubMed ID: 33830675
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genome editing using CRISPR, CAST, and Fanzor systems.
    Song B; Bae S
    Mol Cells; 2024 Jul; 47(7):100086. PubMed ID: 38909984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.